[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112012013035A8 - Fibronectina: quimeras do fator do crescimento - Google Patents

Fibronectina: quimeras do fator do crescimento

Info

Publication number
BR112012013035A8
BR112012013035A8 BR112012013035A BR112012013035A BR112012013035A8 BR 112012013035 A8 BR112012013035 A8 BR 112012013035A8 BR 112012013035 A BR112012013035 A BR 112012013035A BR 112012013035 A BR112012013035 A BR 112012013035A BR 112012013035 A8 BR112012013035 A8 BR 112012013035A8
Authority
BR
Brazil
Prior art keywords
fibronectin
growth factor
protein complexes
chimers
igf
Prior art date
Application number
BR112012013035A
Other languages
English (en)
Other versions
BR112012013035A2 (pt
Inventor
Upton Zee
Van Lonkhuyzen Derek
Original Assignee
Univ Queensland Technology
Qutbluebox Pty Ltd
Tissue Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/627,647 external-priority patent/US20100143442A1/en
Priority claimed from US12/793,386 external-priority patent/US8871709B2/en
Application filed by Univ Queensland Technology, Qutbluebox Pty Ltd, Tissue Therapies Ltd filed Critical Univ Queensland Technology
Publication of BR112012013035A2 publication Critical patent/BR112012013035A2/pt
Publication of BR112012013035A8 publication Critical patent/BR112012013035A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

FIBRONECTINA: QUIMERAS DO FATOR DO CRESCIMENTO. Complexos de proteínas isoladas são fornecidos compreendendo os fatores de crescimento tais como IGF-I, IGF-II, EGF, bFGF ou KGF e fibronectina, ou pelo menos os domínios do mesmo que permitem ligação e ativação tanto um receptor do fator de crescimento quanto a um domínio de ligação ao receptor de integrína da fibronectina. Estes complexos de proteínas incluem proteínas sintéticas, onde o fator de crescimento e as sequências de fibronectina são unidas por uma sequência ligante. Também são fornecidos os usos destes complexos de proteína para estimular ou induzir a migração e/ou proliferação de células na cicatrização de feridas, manipulação de tecidos, tratamentos cosméticos e terapêuticos tais como a substituição da pele, repreenchimento da pele e o tratamento de queimaduras, onde a migração de células epiteliais é necessária. Em outras modalidades, a invenção proporciona a inibição da metástase de células cancerosas, particularmente em relação ao câncer de mama.
BR112012013035A 2009-11-30 2010-11-30 Fibronectina: quimeras do fator do crescimento BR112012013035A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/627,647 US20100143442A1 (en) 2003-02-05 2009-11-30 Growth factor complexes and modulation of cell migration and growth
US12/793,386 US8871709B2 (en) 2003-02-05 2010-06-03 Synthetic chimeric proteins comprising epidermal growth factor and vitronectin
PCT/AU2010/001613 WO2011063477A1 (en) 2009-11-30 2010-11-30 Fibronectin: growth factor chimeras

Publications (2)

Publication Number Publication Date
BR112012013035A2 BR112012013035A2 (pt) 2017-05-16
BR112012013035A8 true BR112012013035A8 (pt) 2018-04-03

Family

ID=44065756

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012013035A BR112012013035A8 (pt) 2009-11-30 2010-11-30 Fibronectina: quimeras do fator do crescimento

Country Status (12)

Country Link
EP (1) EP2507261B1 (pt)
JP (1) JP2013511960A (pt)
KR (1) KR101930916B1 (pt)
CN (1) CN102725308A (pt)
AU (1) AU2010324554B2 (pt)
BR (1) BR112012013035A8 (pt)
CA (1) CA2781474C (pt)
ES (1) ES2619938T3 (pt)
NZ (1) NZ600454A (pt)
RU (1) RU2012127364A (pt)
WO (1) WO2011063477A1 (pt)
ZA (1) ZA201203915B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871709B2 (en) * 2003-02-05 2014-10-28 Queensland University of Technolgy Synthetic chimeric proteins comprising epidermal growth factor and vitronectin
CN103834664B (zh) * 2014-03-27 2016-05-04 吉林大学 重组表皮生长因子egf及其制备方法
JP6953537B2 (ja) * 2016-10-14 2021-10-27 ネオマトリクス・セラピューティクス・インコーポレイテッド 生物活性が改善され好中球エラスターゼ分解に対する感受性が低下した、フィブロネクチンに由来するペプチド
WO2019010533A1 (en) * 2017-07-12 2019-01-17 Factor Therapeutics Limited TREATMENT OF OCULAR DISORDERS
CN110123732A (zh) * 2019-04-03 2019-08-16 广州市拉凯尔干细胞研究所 一种含有纤连蛋白化妆品原料制备方法
CN114040923A (zh) * 2019-04-05 2022-02-11 韩国窑业技术院 利用肌集钙蛋白标签的蛋白质的表达及纯化方法
KR102440312B1 (ko) * 2020-08-28 2022-09-05 한국해양과학기술원 온도안정성을 향상시킨 fgf7 폴리펩타이드 및 그 용도

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849338A (en) 1982-07-16 1989-07-18 Syntex (U.S.A.) Inc. Simultaneous calibration heterogeneous immunoassay
US4843000A (en) 1979-12-26 1989-06-27 Syntex (U.S.A.) Inc. Simultaneous calibration heterogeneous immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
CA1341598C (en) 1988-07-15 2009-09-29 Central Sydney Area Health Service Acid-labile sub-unit (als) of insulin-like growth factor binding proteincomplex
US6090790A (en) 1989-12-14 2000-07-18 Eriksson; Elof Gene delivery by microneedle injection
JP2866134B2 (ja) * 1990-02-05 1999-03-08 寳酒造株式会社 機能性ポリペプチド
JPH06500014A (ja) 1990-07-25 1994-01-06 シンジーン，インコーポレイテッド 多数の核酸相補体を生成させる環状伸長法
US6054122A (en) 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
JP2829405B2 (ja) * 1991-10-14 1998-11-25 寳酒造株式会社 機能性ポリペプチド
US5958764A (en) 1992-04-30 1999-09-28 Baylor College Of Medicine Specific expression vectors and methods of use
WO1994018232A1 (en) 1993-02-12 1994-08-18 Repligen Corporation Methods for generating broadly neutralizing anti-hiv antibodies and antigens capable of eliciting same
US5422252A (en) 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
US5962427A (en) 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
AUPM672594A0 (en) 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
ATE195555T1 (de) * 1994-11-29 2000-09-15 Takara Shuzo Co Verfahren zur herstellung transformierter zellen
WO1997018318A1 (en) * 1995-11-13 1997-05-22 Takara Shuzo Co., Ltd. Method for gene introduction into target cells by retrovirus
ATE199572T1 (de) 1995-11-21 2001-03-15 Univ Yale Unimolekulare segmentamplifikation und bestimmung
US5752019A (en) 1995-12-22 1998-05-12 International Business Machines Corporation System and method for confirmationally-flexible molecular identification
US5835382A (en) 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
US6077987A (en) 1997-09-04 2000-06-20 North Shore-Long Island Jewish Research Institute Genetic engineering of cells to enhance healing and tissue regeneration
AU3192299A (en) 1998-03-18 1999-10-11 Wake Forest University Improved implantable biomaterials, compositions and methods for their preparation and uses thereof
AUPP298498A0 (en) 1998-04-17 1998-05-07 Gropep Pty Ltd Matrix binding factor
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
AU3897200A (en) 1999-03-18 2000-10-04 Hope Heart Institute, The Endothelial cell stimulation by a complex of fibronectin and vascular endothelial growth factor
AU2003900481A0 (en) * 2003-02-05 2003-02-20 Queensland University Of Technology Synthetic modulators of cell migration and growth
JP2008125460A (ja) * 2006-11-22 2008-06-05 Institute Of Physical & Chemical Research フィブリン結合性成長因子
US8759300B2 (en) * 2007-06-14 2014-06-24 The Research Foundation For The State University Of New York Polypeptides and methods of use

Also Published As

Publication number Publication date
BR112012013035A2 (pt) 2017-05-16
EP2507261A4 (en) 2013-04-10
EP2507261A1 (en) 2012-10-10
KR101930916B1 (ko) 2018-12-19
JP2013511960A (ja) 2013-04-11
WO2011063477A1 (en) 2011-06-03
AU2010324554B2 (en) 2014-07-31
AU2010324554A1 (en) 2012-06-21
ES2619938T3 (es) 2017-06-27
EP2507261B1 (en) 2016-12-21
NZ600454A (en) 2014-10-31
CA2781474A1 (en) 2011-06-03
ZA201203915B (en) 2018-11-28
KR20120114277A (ko) 2012-10-16
CN102725308A (zh) 2012-10-10
CA2781474C (en) 2019-06-18
RU2012127364A (ru) 2014-01-10

Similar Documents

Publication Publication Date Title
BR112012013035A8 (pt) Fibronectina: quimeras do fator do crescimento
HK1091216A1 (en) Growth factor complexes and modulation of cell migration and growth
Nikitovic et al. Lumican regulates osteosarcoma cell adhesion by modulating TGFβ2 activity
BR112012030821A2 (pt) vitronectina:fator de crescimento quimeras queratinócitos
BR112013032714A2 (pt) curativo para ferida biorreabsorvível
BR112015000776A2 (pt) Agentes de ligação à rspo3 e usos dos mesmos
AR054175A1 (es) Nuevos anticuerpos anti-igf-ir y usos de los mismos
BR112012009560B8 (pt) método de produção de composição para induzir a regeneração de tecidos através da ativação de plasma rico em plaquetas (prp) e composição
AR061171A1 (es) Proteinas de union al factor de crecimiento de hepatocitos (fch)
BR112012004546A8 (pt) Terapêutica por proteínas ligantes dll4-ligantes
CR20110526A (es) Anticuerpos anti - tnf - alfa y sus usos
ECSP12012211A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
CL2011002756A1 (es) Anticuerpo que se enlaza a la proteina del complemento c3b humana o de cinomolgo; composicion farmaceutica, acido nucleico, vector y celula huesped que comprenden dicho anticuerpo; uso para tratar degeneracion macular relacionada con la edad.
BRPI0906404B8 (pt) construção de fusão com domínio lítico, seus usos, composição farmacêutica, bem como processo para reduzir ou inibir seletivamente a proliferação de uma célula que expressa um receptor, ligante ou antígeno
BR112013018399A2 (pt) anticorpos anti-il1rap e seus usos para tratamento humano
CO7131381A2 (es) Usos terapeúticos de proteínas del factor de crecimiento del fibroplasto
AR079572A1 (es) Anticuerpos que se enlazan a los epitopos de un polipeptido wise
BR112014015322A8 (pt) compostos e composições para inibir a interação de bcl2 com parceiros de ligação
CL2009000862A1 (es) Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer.
BR112014015308A8 (pt) compostos para inibição da interação de bcl2 com contrapartes de ligação
BR112014031788A2 (pt) composições e métodos para o tratamento de diabetes
CU23792A3 (es) Novedosos anticuerpos antiproliferación
BR112014015442A2 (pt) compostos e composições para inibir a interação de bcl2 com parceiros de ligação
AR092736A1 (es) Combinaciones farmaceuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 y agentes anti-vegf-r
MX339001B (es) Proceso para la produccion de parches o apositos de piel autologa mediante cultivo de queratinocitos y fibroblastos autologos con suero autologo para generacion de piel.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: QUTBLUEBOX PTY LTD. (AU)

B25A Requested transfer of rights approved

Owner name: TISSUE THERAPIES LIMITED (AU)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]